

Prof. Dr. med. Hans-Joachim Schmoll

PubMed 1970 – 2018

N Publications; 445 Cumulative Impact Factor: 1697

Web of Science: h (Hirsch-) Factor: 71

Journalbeitrag Originalarbeiten

1. Schwoon DR, Schmoll HJ: (1979) Motivation to participate in cancer screening programmes. SOC SCI MED, 13: 283-6.
IF: 0

1979 Summe Bewertung = 0

Originalarbeiten

1. Schmoll HJ, Niederle N, Achterrath W: (1981) [Etoposide VP 16--213]--a podophyllotoxinderivative with high antitumor activity (author's transl)]. KLIN WOCHENSCHR, 59: 1177-88. [7031350](#)
IF: 0

1981 Summe Bewertung = 0

Originalarbeiten

1. Weiss J, von Roemeling R, Peters HD, Schmoll HJ, Diehl V: (1983) [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone]. DEUT MED WOCHENSCHR, 108: 1428-32. [6192987](#)
IF: 0

1983 Summe Bewertung = 0

Originalarbeiten

1. Gabius HJ, Engelhardt R, Casper J, Reile D, Schumacher S, Schmoll HJ, Graupner G, Cramer F: (1985) Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectin. TUMOR BIOL, 6: 145-56. [4048775](#)
IF: 0

1985 Summe Bewertung = 0

Originalarbeiten

1. Gabius HJ, Engelhardt R, Casper J, Schmoll HJ, Nagel GA, Cramer F: (1986) Comparison of endogenous lectins in human embryonic carcinoma and yolk sac carcinoma. TUMOR BIOL, 6: 471-82. [3010437](#)
IF: 0
2. Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Gluck S, Gorg K, Gramatzki M, et A: (1986) Current results of a multicenter trial in multiple myeloma. ONKOLOGIE, 9: 168-9. [3528964](#)
IF: 0

1986 Summe Bewertung = 0

Summe IF = 0

Originalarbeiten

1. Berdel WE, Berger MR, Falk H, Harstrick A, Danhauser S, Schick HD, Schmoll HJ, Schmahl D, Vogler WR, Rastetter J: (1987) Lack of therapeutic activity of the lipoidal amine CP-46,665 in rodent tumors and human non-seminomatous germ cell tumors growing in nude mice. CANCER LETT, 38: 191-7. [2825966](#)
IF: 0
2. Casper J, Schmoll HJ, Schnaidt U, Fonatsch C: (1987) Cell lines of human germinal cancer. INT J ANDROL, 10: 105-13. [3034787](#)
IF: 0
3. Creutzig A, Polking W, Schmoll HJ, Fabel H, Alexander K: (1987) [Raynaud syndrome and changes in lung function as sequelae of cytostatic therapy of testicular tumors]. MED KLIN-INTENSIVMED, 82: 131-4. [2436030](#)
IF: 0
4. Gabius HJ, Bokemeyer C, Hellmann T, Schmoll HJ: (1987) Targeting of neoglycoprotein-drug conjugates to cultured human embryonal carcinoma cells. J CANCER RES CLIN, 113: 126-30. [3031079](#)
IF: 0
5. Harstrick A, Casper J, Schmoll HJ: (1987) Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts. INT J ANDROL, 10: 139-45. [3034790](#)
IF: 0
6. Schmoll HJ, Schubert I, Arnold H, Dolken G, Hecht T, Bergmann L, Illiger J, Fink U, Preiss J, Pfreundsuh M, et A: (1987) Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin. INT J ANDROL, 10: 311-7. [2438224](#)
IF: 0

1987 Summe Bewertung = 0

Originalarbeiten

1. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, Schmoll HJ, Dietrich H, Hain E: (1988) Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. KLIN WOCHENSCHR, 66: 607-13. [3210656](#)
IF: 0
2. Peest D, Schmoll HJ, Schedel I, Gluck S, Schumacher K, Deicher H: (1988) VBAMDex chemotherapy in advanced multiple myeloma. EUR J HAEMATOL, 40: 245-9. [3356240](#)
IF: 0
3. Verbeek W, Bokemeyer C, Falk H, Schmoll HJ: (1988) Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell lines. J CANCER RES CLIN, 114: 553-8. [3204101](#)
IF: 0
4. Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L: (1988) Etoposide and split-dose cisplatin in small-cell lung cancer. AM J CLIN ONCOL-CANC, 11: 572-8. [2845770](#)
IF: 0
5. Wilke H, Schmoll HJ, Preusser P, Fink U, Stahl M, Schober C, Link H, Freund M, Hanauske A, Meyer HJ, et A: (1988) Folinic acid (CF)/5-fluorouracil (FUra) combinations in advanced gastrointestinal carcinomas. ADV EXP MED BIOL, 244: 233-43. [3073658](#)
IF: 0
6. Wilke H, Schmoll HJ, Schober C, Stahl M, Preusser P, Freund M, Poliwoda H: (1988) Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. BIOMED PHARMACOTHER, 42: 373-80. [3064821](#)
IF: 0

1988 Summe Bewertung = 0

Originalarbeiten

1. Arnemann J, Gradl G, Casper J, Schmoll HJ, Schmidtke J, Fonatsch C: (1989) Characterization of rearranged Y chromosomes in human testicular tumor cell lines. CANCER GENET CYTOGEN, 37: 141-51. [2539248](#)
IF: 0
2. Bokemeyer B, Grote R, Schmoll E, Freise J, Schmoll HJ, Galanski M, Schuler A, Schmidt FW: (1989) [Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin and cisplatin]. DEUT MED WOCHENSCHR, 114: 128-32. [2536606](#)
IF: 0

3. Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ: (1989) Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro. CANCER-AM CANCER SOC, 63: 1079-83. [2645036](#)
IF: 0
4. Schmoll HJ: (1989) The role of ifosfamide in testicular cancer. SEMIN ONCOL, 16(1 Suppl 3): 82-95. [2649987](#)
IF: 0
5. Winkler K, Torggler S, Beron G, Bode U, Gerein V, Jurgens H, Kusnierz-Glaz C, Kotz R, Salzer-Kuntschik M, Schmoll HJ, et A: (1989) [Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative osteosarcoma studies COSS-80 and COSS-82]. ONKOLOGIE, 12: 92-6. [2660050](#)
IF: 0

1989 Summe Bewertung = 0

Summe IF = 0

Originalarbeiten

1. Harstrick A, Casper J, Kohne-Wompner H, Wilke H, Schmoll HJ, Poliwoda H: (1990) Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines. INVEST NEW DRUG, 8: S19-24. [1696245](#)
IF: 0
2. Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H: (1990) Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents. EUR J CANCER, 26: 898-901. [2145935](#)
IF: 0
3. Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wompner CK, Bokemeyer C, Dolken G, Burk K, Poliwoda H: (1990) High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. ANN ONCOL, 1: 375-6. [2261377](#)
IF: 0
4. Jackle-Meyer I, Gwinner W, Baum M, Soose M, Petzoldt R, Schmoll HJ, Stolte H: (1990) Significance of Tamm-Horsfall protein excretion in diabetes mellitus and cisplatin nephrotoxicity. CONTRIB NEPHROL, 83: 124-9. [2100702](#)
IF: 0
5. Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, Meyer HJ, Meyer J, Blum M, Schmoll HJ: (1990) Phase II study of carboplatin in untreated inoperable advanced stomach cancer. EUR J CANCER, 26: 1108-9. [2148891](#)
IF: 0
6. Schmoll HJ: (1990) Progress in treatment of testicular cancer. J CANCER RES CLIN, 116: 112-5. [2312601](#)

IF: 0

7. Schmoll HJ, Harstrick A, Kohne-Wompner CH, Schober C, Wilke H, Poliwoda H: (1990) Modulation of cytotoxic drug activity by dipyridamole. CANCER TREAT REV, 17: 57-65. [2092872](#)

IF: 0

8. Tesch H, Furbass R, Casper J, Lyons J, Bartram CR, Schmoll HJ, Bronson DL: (1990) Cellular oncogenes in human teratocarcinoma cell lines. INT J ANDROL, 13: 377-88. [2283183](#)

IF: 0

1990 Summe Bewertung = 0

Summe IF = 0

Originalarbeiten

1. Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Rath U, Siegert W, et A: (1991) Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma. J CANCER RES CLIN, 117: S198-202. [1665492](#)

IF: 0

2. Harstrick A, Schmoll HJ, Kohne-Wompner CH, Bergmann L, Lammers U, Hohnloser J, Dolken G, Reichardt P, Siegert W, Natt F, et A: (1991) Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. ANN ONCOL, 2: 197-202. [1710481](#)

IF: 0

3. Harstrick A, Schmoll HJ, Wilke H, Kohne-Wompner CH, Stahl M, Schober C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, et A: (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J CLIN ONCOL, 9: 1549-55. [1651992](#)

IF: 0

4. Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ: (1991) Megestrol acetate in cancer cachexia. SEMIN ONCOL, 18(1 Suppl 2): 32-4. [1992534](#)

IF: 0

5. Schmoll HJ: (1991) How should we treat disseminated seminoma? ANN ONCOL, 2: 623-4. [1742217](#)

IF: 0

6. Schmoll HJ: (1991) Introduction: the clinical challenge. EUR J CANCER, 27: S1-2. [1831627](#)

IF: 0

7. Schuppert F, Scheumann GFW, Schöber C, Overbeck J, Schürmeyer T, Schmoll HJ, Dralle H, von zur Mühlen A: (1991) Therapie eines malignen sympathischen

Paraganglioms des Zuckerkandlschen Organs - ein Fallbericht. KLIN WOCHENSCHR, 69: 937 - 942

IF: 0

8. Wilke H, Preusser P, Stahl M, Harstrick A, Meyer HJ, Achterrath W, Schmoll HJ, Seeber S: (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. CANCER CHEMOTH PHARM, 29: 83-4. [1742854](#)

IF: 0

1991 Summe Bewertung = 0

Summe IF = 0

Originalarbeiten

1. Bokemeyer C, Freund M, Schmoll HJ, Rieder H, Fonatsch C: (1992) Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour. ANN ONCOL, 3: 772. [1280461](#)
IF: 0
2. Bokemeyer C, Harstrick A, Schmoll HJ, Kohne-Wompner CH, Schoffski P, Poliwoda H: (1992) Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ANN ONCOL, 3: 487-8. [1498067](#)
IF: 0
3. Bokemeyer C, Harstrick A, Schoffski P, Schmoll HJ, Poliwoda H: (1992) [Germ-cell tumors of the testis. The epidemiological and etiological aspects]. DEUT MED WOCHENSCHR, 117: 1532-7. [1327710](#)
IF: 0
4. Galanski M, Schmoll E, Reichelt S, Bohmer G, Prokop M, Schaefer C, Schuler A, Ringe B, Schmidt FW, Schmoll HJ: (1992) [Chemoembolization of hepatocellular carcinoma in cases of isolated liver involvement]. RADIOLOGE, 32: 49-55. [1314400](#)
IF: 0
5. Harstrick A, Bokemeyer C, Preusser P, Kohne-Wompner CH, Meyer HJ, Stahl M, Knipp H, Schmoll HJ, Wilke H: (1992) Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. CANCER CHEMOTH PHARM, 29: 321-2. [1537080](#)
IF: 0
6. Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM: (1992) Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. SEMIN ONCOL, 19(2 Suppl 3): 105-25. [1373004](#)
IF: 0
7. Schmoll HJ, Bokemeyer C, Harstrick A, Illiger HJ, Metzner B, Ruther U, Osternamm A, Preiss J, Wilke H, Hohnloser J, et A: (1992) Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors. PATHOL BIOL, 39: 961. [1538953](#)

IF: 0

8. Schmoll HJ, Hiddemann W, Rustum Y, Kohne-Wompner CH: (1992) The emerging role for biomodulation of antineoplastic agents. SEMIN ONCOL, 19(2 Suppl 3): 1-3. [1557636](#)

IF: 0

9. Schmoll HJ, Kohne-Wompner CH, Hiddemann W, Knipp H, Wilke H, Bodenstern H, Schoffski P, Bokemeyer C, Lohrmann HP, Preiss J, et A: (1992) Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial. SEMIN ONCOL, 19(2 Suppl 3): 191-6. [1557646](#)

IF: 0

10. Schober C, Bokemeyer C, Stahl M, Wilke HJ, Schmoll HJ, Poliwoda H: (1992) The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. SEMIN ONCOL, 19(2 Suppl 3): 131-5. [1557638](#)

IF: 0

11. Schober C, Kohne-Wompner CH, Schmoll HJ, Stahl M, Wilke HJ, Poliwoda H: (1992) A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. SEMIN ONCOL, 19(2 Suppl 3): 136-40. [1557639](#)

IF: 0

12. Schober C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M, Bokemeyer C, Wilke H, Weiss J: (1992) Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. EUR J CANCER, 28: 1664-6. [1382494](#)

IF: 0

13. Stahl M, Wilke HJ, Seeber S, Schmoll HJ: (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. SEMIN ONCOL, 19(2 Suppl 4): 70-9. [1553577](#)

IF: 0

14. Stahl M, Wilke H, Schmoll HJ, Schober C, Diedrich H, Casper J, Freund M, Poliwoda H: (1992) A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. ANN ONCOL, 3: 167-8. [1606089](#)

IF: 0

15. Wilke H, Stahl M, Schmoll HJ, Preusser P, Fink U, Meyer HJ, Achterrath W, Knipp H, Kohne-Wompner CH, Harstrick A, et A: (1992) Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. SEMIN ONCOL, 19(2 Suppl 3): 215-9. [1557651](#)

IF: 0

1992 Summe Bewertung = 0

Summe IF = 0

Originalarbeiten

1. Bokemeyer C, Kuczyk M, Schoffski P, Schmoll HJ: (1993) Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. J UROLOGY, 150(5 Pt 1): 1509-10. [8411441](#)
IF: 0
2. Bokemeyer C, Luer M, Schmoll HJ, Freund M, Poliwoda H: (1993) Secondary cancer following Hodgkin's disease. ANN ONCOL, 4: 520-1. [8353097](#)
IF: 0
3. Bokemeyer C, Schmoll HJ: (1993) Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). EUR UROL, 23: 223-9; discussion 230. [8097467](#)
IF: 0
4. Bokemeyer C, Schmoll HJ: (1993) Treatment strategies in metastatic testicular cancer. EUR UROL, 23: 50-2. [8390363](#)
IF: 0
5. Bokemeyer C, Schmoll HJ: (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J CLIN ONCOL, 11: 1703-9. [8394879](#)
IF: 0
6. Bokemeyer C, Schmoll HJ, Harstrick A: (1993) Side-effects of GM-CSF treatment in advanced testicular cancer. EUR J CANCER, 29: 924. [8484987](#)
IF: 0
7. Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzner B, Rath U, Hohnloser J, Clemm C, Berdel W, Siegert W, et A: (1993) A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. EUR J CANCER, 29: 2225-31. [8110490](#)
IF: 0
8. Bokemeyer C, Schmoll HJ, Metzner B, Beyer J, Illiger HJ, Kneba M, Ostermann H, Kynast B, Rath U, Poliwoda H: (1993) Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer. ANN HEMATOL, 67: 75-9. [8347733](#)
IF: 0
9. Bokemeyer C, Schmoll HJ, Schoffski P, Harstrick A, Bading M, Poliwoda H: (1993) Bilateral testicular tumours: prevalence and clinical implications. EUR J CANCER, 29: 874-6. [8387319](#)
IF: 0
10. Erlichman C, Fine S, Kerr I, Hoffman W, Gorg C, Schmoll HJ, Preusser P, Senn HJ, Gustavsson B: (1993) Experience with 5FU + L-leucovorin. ADV EXP MED BIOL, 339: 77-9; discussion 97-8. [8178731](#)
IF: 0

11. Grigor KM, Schmoll HJ: (1993) How should we identify high risk testicular tumour patients? Round table discussion. EUR UROL, 23: 207-12. [8386651](#)
IF: 0
12. Grigor KM, Schmoll HJ: (1993) Should high dose chemotherapy with, or without, autologous bone marrow transplant be included in the primary treatment of testicular cancer? Round table discussion. EUR UROL, 23: 240-4. [8386655](#)
IF: 0
13. Grundner-Culemann E, Bokemeyer C, Neubauer V, Shalitin C, Schmoll HJ, Poliwoda H, Benter T: (1993) Analysis of a non-ras 21-kDa protein in patients with metastatic testicular germ-cell tumors. J CANCER RES CLIN, 119: 685-8. [8394368](#)
IF: 0
14. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: (1993) Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. CANCER CHEMOTH PHARM, 33: 43-7. [8269588](#)
IF: 0
15. Harstrick A, Bokemeyer C, Schmoll HJ, Kohne-Wompner CH, Knipp H, Schoffski P, Anagnou J, Wipperman B, Neumann S, Poliwoda H: (1993) A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. CANCER CHEMOTH PHARM, 31: S217-21. [8453702](#)
IF: 0
16. Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y: (1993) Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. EUR J CANCER, 29: 1000-2. [8499130](#)
IF: 0
17. Kohne-Wompner CH, Schmoll HJ: (1993) 5-Fluorouracil modulation in colorectal carcinoma experience of German investigators. ADV EXP MED BIOL, 339: 99-107. [8178734](#)
IF: 0
18. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: (1993) Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J CANCER RES CLIN, 119: 249-52. [8095050](#)
IF: 0
19. Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schober C, Wilke H, Poliwoda H: (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. CANCER-AM CANCER SOC, 72: 237-43. [8508413](#)
IF: 0
20. Schmoll HJ, Seeber S: (1993) [Current developments in chemotherapy of advanced testicular tumors]. UROLOGE, 32: 207-16. [8511834](#)
IF: 0

Originalarbeiten

1. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1994) Treatment intensification in disseminated germ-cell tumors. WORLD J UROL, 12: 207-13. [7820143](#)
IF: 0,561
2. Bokemeyer C, Dunn T, Harstrick A, Lerch T, Poliwoda H, Schmoll HJ: (1994) Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents. INT J CANCER, 56: 452-6. [7906255](#)
IF: 3,276
3. Bokemeyer C, Harstrick A, Ruther U, Metzner B, Illiger HJ, Clemm C, Siegert W, Link H, Ostermann H, Schmoll HJ: (1994) The role of granulocyte-macrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 21(6 Suppl 16): 57-63. [7801148](#)
IF: 2,628
4. Bokemeyer C, Harstrick A, Schmoll HJ: (1994) The use of carboplatin in malignant germ cell tumours. EUR J CANCER, 30: 721-2. [8080698](#)
IF: 0,789
5. Bokemeyer C, Schmoll HJ, Ludwig E, Harstrick A, Dunn T, Casper J: (1994) The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. BRIT J CANCER, 69: 863-7. [8180015](#)
IF: 3,188
6. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J CANCER RES CLIN, 120: 754-7. [7798304](#)
IF: 1,654
7. Bokemeyer C, Schmoll HJ, Poliwoda H: (1994) [Secondary leukemias after etoposide chemotherapy]. DEUT MED WOCHENSCHR, 119: 707-13. [8187625](#)
IF: 0,605
8. Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H: (1994) Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. ANN HEMATOL, 68: 105-10. [8167175](#)
IF: 1,496
9. Derigs HG, Huber C, Schmoll HJ: (1994) [Stage-oriented therapy in nonseminomatous testicular tumors]. DEUT MED WOCHENSCHR, 119: 156-64. [8313845](#)
IF: 0,605
10. Hill BT, Shellard SA, Fichtinger-Schepman AM, Schmoll HJ, Harstrick A: (1994) Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. ANTI-CANCER DRUG,

5: 321-8. [7919457](#)
IF: 1,258

11. Kohne-Wompner CH, Schoffski P, Schmoll HJ: (1994) Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation. ANN ONCOL, 5: 97-104. [8204538](#)
IF: 1,914
12. Link H, Herrmann F, Welte K, Aulitzky WE, Ganser A, Kern WV, Meyer P, Schrappe M, Schmoll HJ, Werdan K, et A: (1994) [Rational therapy with G-CSF and GM-CSF]. MED KLIN-INTENSIVMED, 89: 429-41. [7526144](#)
IF: 0
13. Schmoll HJ: (1994) Colorectal carcinoma: current problems and future perspectives. ANN ONCOL, 5: 115-21. [8204526](#)
IF: 1,914
14. Schmoll HJ: (1994) [Adjuvant chemotherapy in rectal cancer]. CHIRURG, 65: 576-84. [7924595](#)
IF: 0,657
15. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D: (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J CLIN ONCOL, 12: 1223-31. [7911158](#)
IF: 7,507

1994 Summe Bewertung = 6,91752

Summe IF = 28,052

Originalarbeiten

1. Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ: (1995) Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J CLIN ONCOL, 13: 79-86. [7799046](#)
IF: 6,922
2. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ: (1995) Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. EUR J CANCER, 31: 2229-38. [8652248](#)
IF: 2,095
3. Bokemeyer C, Kynast B, Harstrick A, Laage E, Schmoll E, von Wussow P, Schmoll HJ: (1995) No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. CANCER CHEMOTH PHARM, 35: 334-8. [7828277](#)
IF: 1,598

4. Bokemeyer C, Ludwig E, Reile D, Harstrick A, Poliwoda H, Schmoll HJ: (1995) Antitumour activity and toxicity of continuous infusion versus bolus administration of bleomycin in two heterotransplanted human testicular cancer cell lines. ONCOL REP, 2: 161-165
IF: 0,421
5. Bokemeyer C, Schmoll HJ: (1995) Treatment of testicular cancer and the development of secondary malignancies. J CLIN ONCOL, 13: 283-92. [7799032](#)
IF: 6,922
6. Bokemeyer C, Schmoll HJ: (1995) Sekundärneoplasien nach der Therapie maligner Keimzelltumoren des Hodens. STRAHLENTHER ONKOL, 6: 356-357
IF: 0
7. Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W: (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. JNCI-J NATL CANCER I, 87: 58-60. [7666466](#)
IF: 10,165
8. Köhne CH, Hiddemann W, Schüller J, Weiss J, Lohmann HP, Schmitz-Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, Schmoll HJ: (1995) Failure of orally administered Dipyridamole to enhance the antineoplastic activity for Fluorouracil in combination with Leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J CLIN ONCOL, 13: 1201-1208
IF: 6,922
9. Köhne CH, Schmoll HJ: (1995) Therapiestudien zur adjuvanten und palliativen Therapie. ONKOLOGE, 1: 57-60
IF: 0
10. Köhne CH, Schmoll HJ, Wilke H, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Bade J, Strohmeyer G, Schöffski P, Schubert U, Hecker H: (1995) Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer: First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). ANN ONCOL, 6: 461-466
IF: 2,256
11. Kuczyk MA, Bokemeyer C, Fichna B, Truss M, Schmoll HJ, Jonas U: (1995) [Differentiated teratoma as late recurrence of metastatic non-seminomatous testicular germ cell tumor. Case report and clinical problems]. UROLOGE, 34: 480-4. [8848861](#)
IF: 0,381
12. Kuczyk MA, Bokemeyer C, Schmoll HJ, Jonas U: (1995) The prognostic role of alterations of the p53 tumor suppressor gene in superficial and advanced stage bladder cancer. ONKOLOGIE, 18: 202-210
IF: 0,462

13. Rhomberg W, Schmoll HJ, Schneider B: (1995) High frequency of metalworkers among patients with seminomatous tumors of the testis: a case-control study. AM J IND MED, 28: 79-87. [7573077](#)
IF: 0,987
14. Thiel I, Schmoll HJ, Bokemeyer C: (1995) Primary osteogenic sarcoma of the breast: Report of a case and a short review of the literature. ONKOLOGIE, 18: 357-361
IF: 0,462

1995 Summe Bewertung = 9,29561

Summe IF = 39,593

Originalarbeiten

1. Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwercman A, Hata JI, von Keitz A, Looijenga LHJ, Millan JL, Oosterhuis JW, Pera M, Sawada M, Schmoll HJ, Skakkebaek NE, van Putten W, Stern P: (1996) Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumors. INT J CANCER, 66: 806-816
IF: 3,534
2. Berger C, Bokemeyer C, Schuppert F, Schmoll HJ: (1996) Endocrinological late effects after chemotherapy for testicular cancer. BRIT J CANCER, 73: 1108-1114
IF: 3,666
3. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1996) Hochdosischemotherapie bei Hodentumoren. ONKOLOGE, 2: 28-32
IF: 0
4. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W: (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J CLIN ONCOL, 14: 2638-2645
IF: 7,881
5. Beyer J, Kramer A, Mandanas R, Linkesch W, Greinix A, Droz JP, Culine S, Diehl A, Bokemeyer C, Schmoll HJ, Einhorn LH, Nichols CR, Siegert W: (1996) Treatment outcome of high-dose chemotherapy as salvage treatment in male germ cell tumors: a multivariate analysis of prognostic factors. J CLIN ONCOL, 14: 2638-2645
IF: 7,881
6. Bokemeyer C, Beyer J, Metzner B, R  ther U, Wei  bach L, K  hrmann U, Verbeek W, Harstrick A, Schmoll HJ: (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory cancer. ANN ONCOL, 7: 31-34
IF: 2,736
7. Bokemeyer C, Fels LM, Dunn TA, Voigt W, Gaedeke J, Schmoll HJ, Stolte H: (1996) Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide antitumor activity. BRIT J CANCER, 74: 2036-2041

IF: 3,666

8. Bokemeyer C, Köhrmann O, Tischler J, Weißbach L, Räh U, Haupt A, Schöffski P, Schmoll HJ: (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good risk metastatic non-seminomatous germ cell tumors. ANN ONCOL, 7: 1015-1022
IF: 2,736
9. Bokemeyer C, Kuczyk MA, Dunn TA, Serth T, Hartmann K, Jonasson J, Jonas U, Schmoll HJ: (1996) Expression of stem cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumors. J CANCER RES CLIN, 122: 301-306
IF: 1,093
10. Bokemeyer C, Kuczyk MA, Köhne CH, Einsele H, Kynast B, Schmoll HJ: (1996) Hematopoietic growth factors and treatment of testicular cancer: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 72: 1-9
IF: 1,206
11. Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ: (1996) Treatment of testicular cancer and hematopoietic growth factors: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 7: 1-9
IF: 1,206
12. Bokemeyer C, Kuczyk MA, Köhne H, Haupt A, Schmoll HJ: (1996) Das Risiko sekundärer Neoplasien nach Behandlung maligner Keimzelltumoren des Hodens. MED KLIN-INTENSIVMED, 91: 703-710
IF: 0
13. Bokemeyer C, Kuczyk MA, Serth, Hartmann JT, Schmoll HJ, Jonas U, Kanz L: (1996) Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J CANCER RES CLIN, 122: 575-584
IF: 1,093
14. Bokemyer C, Berger C, Kuczyk MA, Schmoll HJ: (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J CLIN ONCOL, 14: 2923-2932
IF: 7,881
15. Borchard E, Engelhardt, Frommhold, Hartung, Hermanek, Herrmann, Hossfeld, Junginger, Kirchner, Kreuser, Meyer, Müller, Pichlmaier, Queißer, Schlag, Schmoll, Stock, Wilke: (1996) Konsens der CAO, AOI und ARO zur Diagnostik und Therapie des primären Magenlymphoms. ONKOLOGIE, 19: 360-363
IF: 0,451
16. Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J: (1996) Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. ANTI-CANCER DRUG, 7: 1-5
IF: 1,397

17. Erlichman C, Fine S, Kerr I, Hoffmann W, Görg C, Schmoll HJ, Preusser P, Thuerlimann B, Gustavsson B: (1996) A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. AM J CLIN ONCOL-CANC, 19: 26-31
IF: 0,921

18. Fels LM, Bokemeyer C, van Rhee J, Schmoll HJ, Stolte H: (1996) Evaluation of late nephrotoxicity in long-term survivors of Hodgkin's disease. ONCOLOGY-BASEL, 53: 73-78
IF: 2,097

19. Hartmann JT, Thiel I, Schmoll HJ, Einsele H, Kanz L, Bokemeyer C: (1996) Malignant fibrous histiocytoma of bone - review of thirteen cases. ONCOL REP, 3: 1-5
IF: 0,476

20. Rambusch EG, Schuppert F, Müller-Kunert E, Stöcker W, Bokemeyer C, Schmoll HJ, von zur Mühlen A: (1996) Zytokintherapie und Endokrinium: Ist es sinnvoll, mehr als die Schilddrüse zu untersuchen? MED KLIN-INTENSIVMED, 91: 59-65
IF: 0

21. Rüter U, Nunnensiek C, Sessler R, Stilz S, Ulshöfer T, Müller HAG, Bader H, Bokemeyer C, Schmoll HJ, Toomes H, Jipp P: (1996) Efficacy of antiestrogen treatment in a benign metastasizing leiomyoma with paraneoplastic estradiol production. ONCOL REP, 3: 293-299
IF: 0,476

22. Schmoll HJ: (1996) Die Therapie von Keimzelltumoren: Modell für eine interdisziplinäre Behandlungsstrategie. MED KLIN-INTENSIVMED, 3: 80-84
IF: 0

23. Schmoll HJ: (1996) Development of Treatment for Advanced Colorectal Cancer: Infusional 5-FU and the role of new agents. EUR J CANCER, 32: S18-22
IF: 2,017

24. Schmoll HJ, Bokemeyer C: (1996) Sequential intermediate high-dose chemotherapy in the primary treatment of poor risk testicular cancer. BONE MARROW TRANSPL, 18: 48-49
IF: 2,771

1996 Summe Bewertung = 11,64513

Summe IF = 55,185

Originalarbeiten

1. Bamberg M, Schmoll HJ, Weißbach L, Beyer J, Bokemeyer C, Harstrick A, Hörtl W, Souchon R, Vogler H: (1997) An interdisciplinary consensus conference on the diagnosis and therapy of testicular tumors. STRAHLENTHER ONKOL, 173: 397-406
IF: 0

2. Berkovic D, Grundel O, Berkovic K, Wildfang I, Hess CF, Schmoll HJ: (1997) Synergistic cytotoxic effects of either phospholipid analogues and ionizing radiation in human

carcinoma cells. *RADIOTHER ONCOL*, 43: 293-301

IF: 1,924

3. Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: (1997) A Phase I/ II Study of Sequential, Dose-Escalated, High-Dose Ifosfamide plus Doxorubicin with Peripheral Blood Stem Cell Support for the Treatment of Patients with Advanced Soft Tissue Sarcomas. *CANCER-AM CANCER SOC*, 6: 1221-1227
IF: 3,296
4. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ: (1997) Treatment of brain metastases in patients with testicular cancer. *J CLIN ONCOL*, 15: 1449-1454
IF: 7,878
5. Dunn TA, Schmoll HJ, Grünewald V, Bokemeyer C, Casper J: (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. *INVEST NEW DRUG*, 15: 109-114
IF: 0,543
6. Dunn T, Schmoll HJ, Grünewald V, Casper J, Bokemeyer C: (1997) Pre-clinical activity of taxol in nonseminomatous germ cell tumor cell lines and nude mouse xenografts. *INVEST NEW DRUG*, 15: 91-98
IF: 0,543
7. Harstrick A, Köhne CH, Hiddemann W, Preusser P, Berns T, Seeber S, Wilke H, Schmoll HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N-(phosphonacety)-L-aspartate (PALA) in inactive advanced pancreatic carcinoma. *ANN ONCOL*, 8: 917-918
IF: 2,548
8. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C: (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumors. *EUR J CANCER*, 33: 843-847
IF: 2,407
9. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C: (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. *ANN ONCOL*, 8: 531-538
IF: 2,548
10. Hartmann JT, Schmoll HJ, Thiel I, Kanz L, Bokemeyer C: (1997) Klinische Verlaufsbeobachtung von Patienten mit malignem fibrösen Histiozytom des Knochens und Übersicht zur chemotherapeutischen Behandlung. *TUMORDIAGN THER*, 1: Jan 34
IF: 0,148
11. Hartmann, Schmoll E, Bokemeyer C, Fety, Lucas, D'Agay, Schmoll HJ: (1997) Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver

metastases from colorectal carcinoma. ONCOL REP, 4: 167-172

IF: 0,407

12. Köhne C, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N-(phosphonacety)-L-aspartate in Patients with Advanced Colorectal Cancer. Results of a Phase II Study. EUR J CANCER, 33: 1896-1899

IF: 2,407

13. Köhne C, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J, Rauschecker H, Hill H, Käufer C, Fischer JT, Ohl U, Urbanitz D, Balleisen L, Schmoll HJ: (1997) Phase II Evaluation of 5-Flourouracil plus Folinic acid and alpha 2b-interferon in metastatic colorectal cancer. ONCOLOGY-BASEL, 54: 98-101

IF: 2,141

14. Malek NP, Casper J, Looijenga LH, Strohmeyer T, Schmoll HJ, Nordheim A, Janknecht R: (1997) Quantification of additional short arms of chromosome 12 in germ cell tumors using the polymerase chain reaction. EUR J CANCER, 33: 1488-1494

IF: 2,407

15. Schmoll HJ: (1997) Prognostic factors for advanced seminoma - a solid basis for clinical trials (Editorial). EUR J CANCER, 9: 1347-1350

IF: 2,407

16. Schmoll HJ, Bamberg M, Weißbach L: (1997) Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. ONKOLOGIE, 20: 164-170

IF: 0,328

17. Schmoll HJ, Büchele T, Schöber C: (1997) The role of second line chemotherapy in colorectal cancer. ONKOLOGIE, 20: 288-294

IF: 0,328

18. Schöber C, Galanski M, Jörgensen M, Schmoll HJ: (1997) Management of endocrine pancreatic tumors. WIEN KLIN WOCHENSCHR, 147: 18-23

IF: 0,411

19. Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ: (1997) Analysis of the MHC-Class I antigen presentation machinery in a human embryonal carcinoma cell line: evidence for suppression of TAP, LMP and MHC class I expression. SCAND J IMMUNOL, 46: 625-632

IF: 1,749

20. Weißbach L, Bamberg M, Schmoll HJ: (1997) Interdisciplinary consensus conference on diagnosis and therapy of testicular cancer. UROLOGE, 36: 362-368

IF: 0,513

1. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1998) Salvagetherapie rezidivierender und refraktärer Hodentumoren. ONKOLOGE, 4: 541-546
IF: 0
2. Beyer J, Schmoll HJ: (1998) Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. ONKOLOGE, 4: 518-523
IF: 0
3. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L: (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. BRIT J CANCER, 77: 1355-1362
IF: 3,036
4. Bokemeyer C, Gerl A, Harstrick A, Schmoll HJ: (1998) Therapie des fortgeschrittenen nichtseminomatösen Keimzelltumors. ONKOLOGE, 4: 532-540
IF: 0
5. Bokemeyer T, Harstrick A, Beyer J, Metzner B, Rütger U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A, Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ: (1998) The use of dose-intensified chemotherapy in the treatment of metastatic non-seminomatous testicular germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 25: 24-32
IF: 2,252
6. Dunn T, Schmoll HJ, Rie C, Hartmann K, Casper J: (1998) Production and pre-clinical significance of hematopoietic peptide growth factor (HPGF) in human non-seminomatous germ cell tumor (NSGCT) cell lines. J CANCER RES CLIN, 124: 435-443
IF: 1,183
7. Hartmann JT, Köhne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C: (1998) Is continuous 24-hour infusion of 5-Fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II Study. ONCOLOGY-BASEL, 55: 320-325
IF: 2,858
8. Hartmann JT, Schmoll E, Bokemeyer C, Fety R, Lucas C, Giroux B, Schmoll HJ: (1998) Phase I Pharmacological Study of Intra-arterially Infused Fotemustine for Colorectal Liver Metastases. EUR J CANCER, 34: 87-91
IF: 2,743
9. Köhne CH, Schöffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstrick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ: (1998) Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J CLIN ONCOL, 16: 418-426
IF: 8,228

10. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C: (1998) Secondary leukemia following high cumulative doses for Etoposide in Patients treated for advanced germ cell tumors. J CLIN ONCOL, 16: 3386-3391
IF: 8,228
11. Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Saß G, Seeber S, Thiel E, Berdel WE: (1998) Phase I Clinical and Pharmacokinetic Study of Titanocene Dichloride in adults with advanced solid tumors. CLIN CANCER RES, 4: 2701-2708
IF: 2,941
12. Schmoll HJ: (1998) Is there a standard adjuvant treatment for colon cancer? (Editorial). EUR J CANCER, 34: 1659-1663
IF: 2,743
13. Schmoll HJ: (1998) Is there a standard adjuvant treatment for rectal cancer? (Editorial). EUR J CANCER, 34: 1827-1835
IF: 2,743
14. Schmoll HJ, Beyer J: (1998) Prognostic factors in metastatic germ cell tumors. SEMIN ONCOL, 25: 174-186
IF: 2,252
15. Schmoll HJ, Weißbach L, Bamberg M: (1998) Editorial: Therapie des Hodentumors: das Zauberwort heißt Interdisziplinarität. ONKOLOGE, 4: 471-472
IF: 0

1998 Summe Bewertung = 11,94738

Summe IF = 39,207

Originalarbeiten

1. Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ: (1999) Gemcitabine in patients with relapsed or Cisplatin-refractory testicular cancer. J CLIN ONCOL, 17: 512-516
IF: 7,963
2. Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L: (1999) Treatment of patients with Cisplatin-refractory testicular germ-cell cancer. INT J CANCER, 83: 848-851
IF: 3,545
3. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C: (1999) First-Line High-Dose Chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J CLIN ONCOL, 17: 3450-3456
IF: 7,963

4. Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll HJ: (1999) Diagnostisches und therapeutisches Management der oberen Einflusstauung. MED KLIN-INTENSIVMED, 94: 681-684
IF: 0
5. Dempke W, Büchele T, Wolf HH, Grothey A, Schmoll HJ: (1999) Diagnostik und Therapie maligner Pleura- und Perikardergüsse. ONKOLOGIE, 22: 526-529
IF: 0,382
6. Dempke W, Voigt W, Grothey A, Schmoll HJ: (1999) Preferential repair of the N-ras gene in K562 cells after exposure to cisplatin. ANTI-CANCER DRUG, 10: 545-549
IF: 1,594
7. Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mrad GM, Germa-Luch JR, Pont J, Schmoll HJ, Tjulandin S: (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. CANCER-AM CANCER SOC, 85: 988-997
IF: 3,632
8. Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ: (1999) The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J CANCER RES CLIN, 125: 166-173
IF: 1,052
9. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C: (1999) Long-term effects on sexual function and fertility after treatment of testicular cancer. BRIT J CANCER, 80: 801-807
IF: 3,282
10. Kellner O, Dempke W, Schmoll HJ: (1999) Glukose-Infusionen - eine mögliche effektive Therapieoption bei der Ifosfamid-induzierten Enzephalopathie. DEUT MED WOCHENSCHR, 124: 1086-1087
IF: 0,684
11. Schmoll HJ: (1999) Standards in der Behandlung kolorektaler Karzinome - Wunsch und Wirklichkeit. ONCOLOGY-BASEL, 99: 6-7
IF: 2,684
12. Schmoll HJ: (1999) Treatment of testicular tumours based on risk factors. CURR OPIN UROL, 9: 431-438
IF: 0
13. Schmoll HJ, Büchele T, Grothey A, Dempke W: (1999) Where do we stand with 5-FU? SEMIN ONCOL, 26: 589-605
IF: 2,986

1999 Summe Bewertung = 8,43815

Summe IF = 35,767

Originalarbeiten

1. Brieger P, Marneros A, Wolf HH, Schmoll HJ: (2000) Manic episode in an ifosfamide-treated patient. GEN HOSP PSYCHIAT, 22: 52-3 [10766557](#)
IF: 1,512
2. Büchele T, Grothey A, Schmoll HJ: (2000) Neue Perspektiven mit neuen Zytostatika in der Behandlung des kolorektalen Karzinoms. ONKOLOGE, 6: 410-419
IF: 0
3. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ: (2000) Cisplatin resistance and oncogenes - a review. ANTI-CANCER DRUG, 11: 225-236
IF: 1,57
4. Dempke W, von Poblozki A, Grothey A, Schmoll HJ: (2000) Human hematopoietic growth factors: old lessons and new perspectives. ANTICANCER RES, 20: 5155-5164
IF: 1,331
5. Grothey A, Kegel T, Dempke W, Schmoll HJ: (2000) Systemische Therapie des hepatozellulären Karzinoms. ONKOLOGE, 6: 327-335
IF: 0
6. Kellner O, Voigt W, Schneyer U, Dempke W, Schmoll HJ: (2000) HCG-induced hyperthyreosis in germ cell cancer. ANTICANCER RES, 20: 5135-8
IF: 1,331
7. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schöffski P, Gerigs G, Rüther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C: (2000) First-Line High-Dose chemotherapy + radiation therapy in patients with metastatic germ-cell cancer and brain metastases. ANN ONCOL, 11: 553-559
IF: 3,249
8. Schmiegel W, Adler G, Frühmorgen P, Fölsch U, Greaven U, Layer P, Petrasch S, Porschen R, Pox C, Sauerbruch T, Schmoll HJ, Zeitz M: (2000) Kolorektales Karzinom: Prävention und Früherkennung in der asymptomatischen Bevölkerung - Vorsorge bei Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen. Z GASTROENTEROL, 38: 49-75
IF: 0,887
9. Schmoll HJ: (2000) Aktive spezifische Immunotherapie (ASI) beim Kolonkarzinom. STRAHLENTHER ONKOL, 176: 47-48
IF: 2,846
10. Schmoll HJ, Krege S, Souchon R: (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf der Grundlage evidenzbasierter Medizin. ONKOLOGIE, 23: 603-613
IF: 0,64
11. Schneider I, Rettkowski O, Markau S, Wolf HH, Deuber HJ, Schmoll HJ, Osten B: (2000) Erfassung der Nierenschädigung beim Plasmozytom durch die Cystatin C-Bestimmung im Serum. LABORATORIUMSMEDIZIN, 24: 1900

IF: 0

12. Souchon R, Krege S, Schmoll HJ, Albers P, Veyer J, Bokemeyer C, Claßena J, Dieckmann KP, Hartmann M, Heidenreich A, Höltl W, Kliesch S, Köhrmann KU, Kuczyk M, Schmidberger H, Weinknecht S, Winter E, Wittekind C, Bamberg M: (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. STRAHLENTHER ONKOL, 176: 388-405
IF: 2,846
13. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstern H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA: (2000) Final results of a randomized phase II trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusion fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J CLIN ONCOL, 18: 2648-2657
IF: 8,773
14. Voigt W, Bulankin A, Müller T, Schöber C, Grothey A, Hoang-Vu C, Schmoll HJ: (2000) Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. CLIN CANCER RES, 6: 2087-2093
IF: 4,643
15. von Poblocki A, Dempke W, Schmoll HJ: (2000) Carboxypeptidase-G2-Rescue bei einer Patientin mit Methotrexat-induziertem Nierenversagen. MED KLIN-INTENSIVMED, 95: 457-460
IF: 0

2000 Summe Bewertung = 6,64826

Summe IF = 29,628

Originalarbeiten

1. Bokemeyer C, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Einhorn L, Nichols CR, Hartmann JT: (2001) Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. CANCER-AM CANCER SOC, 91: 1394-1401
IF: 3,909
2. Dempke W, Rie C, Grothey A, Schmoll HJ: (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J CANCER RES CLIN, 127: 411-417
IF: 2,194
3. Dempke W, Schmoll HJ: (2001) Mögliche neue Indikationen für die Therapie mit Erythropetin. MED KLIN-INTENSIVMED, 96: 467-474
IF: 0
4. Dempke W, von Poblocki A, Kellner O, Wolf HH, Schmoll HJ: (2001) Hämorrhagische Diathese als Erstsymptom eines Magenkarzinoms. WIEN KLIN WOCHENSCHR, 112:

1053-1058

IF: 0,646

5. Fittkau M, Gerlach R, Schmoll HJ: (2001) Protective effect of oral phosphatidylcholine on radiation-induced release of intestinal peptidases in rats. J CANCER RES CLIN, 127: 444
IF: 2,194
6. Fittkau M, Grothey A, Gerlach R, Schmoll HJ: (2001) A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. J CANCER RES CLIN, 127: 96-100
IF: 2,194
7. Fizazi K, Tjulandin S, Salvioni R, Germa-Luch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C: (2001) Viable malignant cells after primary Chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy - results from an international study group. J CLIN ONCOL, 19: 2647-2657
IF: 8,53
8. Grothey A, Schmoll HJ: (2001) New Chemotherapy approaches in colorectal cancer. CURR OPIN ONCOL, 13: 275-286
IF: 0
9. Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Bokemeyer C: (2001) Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis. J CLIN ONCOL, 19: 1641-1648
IF: 8,53
10. Hoff PM, Cassidy J, Schmoll HJ: (2001) The evolution of Fluoropyrimidine Therapy: From Intravenous to Oral. ONCOLOGIST, 6: 3-11
IF: 0
11. Kellner O, Krüger W, Schmoll HJ: (2001) Standardmanagement von Fieber unklarer Genese (FUO) bei hämatologischen oder onkologischen Patienten in der Neutropenie. PHARMAZIE, 3: 03. Apr
IF: 0,498
12. Krege S, Souchon R, Schmoll HJ: (2001) Interdisciplinary consensus on Diagnosis and Treatment of Testicular Germ Cell Tumors: Result of an Update Conference on Evidence-Based Medicine (EBM). EUR UROL, 40: 372-391
IF: 2,304
13. Krege S, Souchon R, Schmoll HJ: (2001) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin. UROLOGE, 2: 137-147

IF: 0,497

14. Rades D, Kühnel G, Wildfang I, Bömer AR, Schmoll HJ, Knapp W, Karstens JH: (2001) Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. ANN ONCOL, 12: 1605-1609

IF: 3,153

15. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel W, Kanz L, Siegert W: (2001) Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J CLIN ONCOL, 19: 81-88

IF: 8,53

16. Schmoll HJ: (2001) Kolorektale Karzinome. ONKOLOGIE, 24: 1-8

IF: 0,573

17. Schmoll HJ, Cassidy J: (2001) Integrating Oxaliplatin into the Management of Colorectal Cancer. ONCOLOGIST, 6: 24-28

IF: 0

18. Wolf HH, Förster W, Schöber C, Grothey A, Dempke W, Schmoll HJ: (2001) Cyclooxygenase-2-inhibitors in colon cancer. ONKOLOGIE, ?: #

IF: 0,573

2001 Summe Bewertung = 5,20094

Summe IF = 44,325

Originalarbeiten

1. Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Hartmann JT: (2002) Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J CLIN ONCOL, 20: 1864-73. [11919246](#)
IF: 9,868
2. Fittkau M, Gerlach R, Schmoll HJ: (2002) Phosphatidylcholine does not protect rats against 5-fluorouracil/ folinic acid-induced damage of the intestinal luminal mucosa. J CANCER RES CLIN, 128: 80-84
IF: 2,197
3. Grothey A, Kellermann L, Schmoll HJ: (2002) [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms]. MED KLIN-INTENSIVMED, 97: 270-7. [12078387](#)
IF: 0
4. Krüger WH, Wolf HH, Voigt W, Skibbe T, Schmoll HJ: (2002) Detection of an occult B-cell lymphoma in the donor's bone marrow prior to HLA-matched sibling

transplantation. J HEMATOTH STEM CELL, 11: 169-70 [11983090](#)

IF: 1,628

5. Mantovani L, Hasenclever D, Krahl R, Ponisch W, Herold M, Pasold R, Fiedler F, Dolken G, Kampfe D, Schmoll HJ, Subert R, Kubel M, Niederwieser D, Helbig W: (2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. LEUKEMIA LYMPHOMA, 43: 265-74. [11999557](#)
IF: 1,335
6. Schmoll HJ: (2002) Extragonadal germ cell tumors. ANN ONCOL, 13: 265-72. [12401700](#)
IF: 3,114
7. Schmoll HJ: (2002) The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. SEMIN ONCOL, 29(5 Suppl 15): 34-9. [12422306](#)
IF: 3,5
8. Schmoll HJ: (2002) Is there a role of high-dose chemotherapy in lymphoma and solid tumours: The present state of the art. CRIT REV ONCOL HEMAT, 41: 127-128
IF: 2,758
9. Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Johnston P, Kerr D, Koehne CH, Labianca R, Minsky B, Nordlinger B, Roth A, Rougier P, Schmoll HJ: (2002) Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). EUR J CANCER, 38: 1429-36. [12110487](#)
IF: 3,562
10. Voigt W, Behrmann C, Schlüter A, Bläser F, Wunderlich D, Harba A, Kegel T, Grothey A, Schmoll E, Schmoll HJ: (2002) Hepatic transcatheter arterial chemoembolisation in refractory liver metastasis of colorectal cancer with Mitomycin C, Interferon-ALPHA2b and Dexamethasone mixed with Amilomer DSM 45/25 (Sperex®) followed by Oxaliplatin, Folinic acid and 5-Fluorouracil - feasibility and preliminary results. ONKOLOGIE, 25: 158-164
IF: 0,855
11. Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ: (2002) A new chemoembolization protocol in refractory liver metastasis of colorectal cancer--a feasibility study. ONKOLOGIE, 25: 158-64. [12006767](#)
IF: 0,855

2002 Summe Bewertung = 12,77012

Summe IF = 29,672

Originalarbeiten

1. Arnold D, Grothey A, Schmoll HJ: (2003) Neue Entwicklungen in der systemischen Therapie des fortgeschrittenen Kolonkarzinoms. ONKOLOGE, 9: 847-859

IF: 0, anteiliger IF: 0

2. Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ, Kollmannsberger C, Boehlke I, Kanz L, Hartmann JT: (2003) First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. BRIT J CANCER, 89: 29-35. [12838296](#)
IF: 3,894
3. Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ: (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J CLIN ONCOL, 21: 3721-8.
IF: 10,864
4. Kollmannsberger C, Schleucher N, Rick O, Metzner B, Hartmann JT, Schoffski P, Beyer J, Casper J, Sosada M, Schmoll HJ, Bohlke I, Meisner C, Kanz L, Bokemeyer C: (2003) Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. EUR J CANCER, 39: 775-82. [12651203](#)
IF: 3,694
5. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ: (2003) Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. CANCER RES, 63: 513-21. [12543810](#)
IF: 8,649
6. Paschke R, Kalbitz J, Paetz C, Luckner M, Mueller T, Schmoll HJ, Mueller H, Sorkau E, Sinn E: (2003) Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J INORG BIOCHEM, 94: 335-42. [12667704](#)
IF: 2,343
7. Paschke R, Paetz C, Mueller T, Schmoll HJ, Mueller H, Sorkau E, Sinn E: (2003) Biomolecules linked to transition metal complexes-new chances for chemotherapy. CURR MED CHEM, 10: 2033-44. [12871101](#)
IF: 4,409
8. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R: (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J CLIN ONCOL, 21: 3098-104. [12915600](#)
IF: 10,864
9. Schmoll HJ: (2003) Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. ANTI-CANCER DRUG, 14: 695-702. [14551502](#)

IF: 1,938

10. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C: (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J CLIN ONCOL, 21: 4083-91.

IF: 10,864

2003 Summe Bewertung = 13,63867

Summe IF = 57,519

Originalarbeiten

1. Arnold D, Schmoll HJ: (2004) Palliative Systemtherapie beim metastasierten Ösophaguskarzinom. Sind neue Therapieansätze in Sicht? ONKOLOGE, 10: 1202-1214
IF: 0
2. Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A, Clemm C, Gerl A, Meisner C, Ruckerl CP, Schmoll HJ, Kanz L, Oliver T: (2004) Metastatic seminoma treated with either single agent carboplatin or cisplatin based combination chemotherapy: a pooled analysis of two randomised trials. BRIT J CANCER, 91: 683-687
IF: 3,742
3. Fittkau M, Voigt W, Holzhausen HJ, Schmoll HJ: (2004) Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J CANCER RES CLIN, 25: 388-394 [15160289](#)
IF: 2,409
4. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J CLIN ONCOL, 1: 1209-1214
IF: 9,835
5. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A: (2004) Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. ANN HEMATOL, 83: 498-503
IF: 1,299
6. Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A: (2004) Phase II Trial of Capecitabine/ Irinotecan and Capecitabine/ Oxaliplatin in Advanced Colorectal Cancer. CLIN COLORECTAL CANC, 4: 46-50
IF: 0
7. Kegel T, Schmoll HJ: (2004) Systemische Chemotherapie neuroendokriner Tumoren. ONKOLOGE, 10: 621-633

IF: 0

8. Rades D, Fehlauser F, Stalpers LJ, Wildfang I, Zschenker O, Schild SE, Schmoll HJ, Karstens JH, Alberti W: (2004) A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. *CANCER-AM CANCER SOC*, 101: 2687-2692
IF: 1,654
9. Schmiegel W, Pox C, Adler G, Fleig W, Fölsch UR, Frühmorgen P, Graeven U, Hohenberger W, Holstege A, Junginger T, Kühnbacher T, Porschen R, Propping P, Riemann JF, Sauer R, Sauerbruch T, Schmoll HJ, Zeitz M, Selbmann HK: (2004) S3-Leitlinienkonferenz "Kolorektales Karzinom". *Z GASTROENTEROL*, 10: 1129-1177
IF: 1
10. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, De Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, De Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, De Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia Del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Potttek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, Von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C: (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). *ANN ONCOL*, 15: 1377-99. [15319245](#)
IF: 4,335

2004 Summe Bewertung = 5,7797

Summe IF = 24,267

Originalarbeiten

1. Arnold D, Schmoll HJ: (2005) (Neo-)adjuvant treatments in colorectal cancer. *ANN ONCOL*, 16: ii133-ii140
IF: 4,319
2. Diaz-Rubio E, Schmoll HJ: (2005) The future development of bevacizumab in colorectal cancer. *ONCOLOGY-BASEL*, 69: 34-45
IF: 1,985
3. Diaz-Rubio E, Schmoll HJ: (2005) Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. *ONCOLOGY-BASEL*, 69: 1-3
IF: 1,985
4. Hochster H, Kettner E, Kroning H, Becker K, Lordick F, Ramanathan RK, Macdonald J, Hong S, John W, Schmoll HJ: (2005) Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. *CLIN COLORECTAL CANC*,

5: 257-262

IF: 0

5. Jordan K, Grothey A, Grothe W, Kegel T, Wolf HH, Schmoll HJ: (2005) Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. EUR J HAEMATOL, 74: 263-6 [15693798](#)
IF: 2,004
6. Jordan K, Grothe W, Schmoll HJ: (2005) Paravasation von Zytostatika: Prävention und Therapie. DEUT MED WOCHENSCHR, 130: 33-37
IF: 0,653
7. Jordan K, Grothey A, Kegel T, Fibich C, Schoeber C, Schmoll HJ: (2005) Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. ONKOLOGIE, 28: 88-92
IF: 1,206
8. Jordan K, Hinke A, Grothey A, Schmoll HJ: (2005) Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. SUPPORT CARE CANCER, 31: 26-31
IF: 1,59
9. Jordan K, Kasper C, Schmoll HJ: (2005) Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. EUR J CANCER, 41: 199-205
IF: 3,706
10. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M, West GSG: (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. LANCET, 366: 1935-44 [16325695](#)
IF: 23,407
11. Pico JL, Rosti G, Kramar A, Wandt H, Kza V, Salvioni R, Theodore C, Lelli G, Siegert W, Horwich A, Marangolo M, Linkesch W, Pizzocaro G, Schmoll HJ, Bozy J, Droz JP, Biron P: (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. ANN ONCOL, 16: 1152-1159
IF: 4,319
12. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M, Kahan JP: (2005) OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J CLIN ONCOL, 23: 7125-7134
IF: 11,81

13. Renniecke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C, Dempke W: (2005) Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. ANTICANCER RES, 25: 1147-55 [15868958](#)
IF: 1,604
14. Schmiegel W, Pox C, Adler G, Fleig W, Folsch UR, Fruhmorgen P, Graeven U, Hohenberger W, Holstege A, Kuhlbacher T, Prosch R, Propping P, Riemann JF, Sauer R, Sauberbruch T, Schmoll HJ, Zeitz M, Selbmann He: (2005) S3-guideline conference "Colorectal Cancer" 2004. DEUT MED WOCHENSCHR, 8; 130 (Suppl. 1): S5-53
IF: 0,653
15. Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ: (2005) Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J CANCER RES CLIN, 131: 585-590
IF: 2,503

2005 Summe Bewertung = 8,79177

Summe IF = 61,744

Originalarbeiten

1. Arnold D, Peinert S, Voigt W, Schmoll HJ: (2006) Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. ONCOLOGIST, 11: 602-611
IF: 5,206
2. Arnold D, Siewczynski R, Schmoll HJ: (2006) The integration of targeted agents into systemic therapy of metastatic colorectal cancer. ANN ONCOL, 17: x122-x128
IF: 5,179
3. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schoeffski P, Schmoll H, Van Cutsem E, Koehne CH: (2006) Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? EUR J CANCER, 42: 42-49
IF: 4,167
4. Jordan K, Voigt W, Schmoll HJ: (2006) Chemotherapy induced nausea and vomiting - a practical treatment approach. DEUT MED WOCHENSCHR, Aug 25; 131 (34-35): 1869-1872
IF: 0,584
5. Krege S, Boergermann C, Baschek R, Hinke A, Pottke T, Kliesch S, Dieckmann KP, Albers P, Knutzen B, Weinknecht S, Schmoll HJ, Beyer J, Ruebben H: (2006) Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). ANN ONCOL, 17: 276-280
IF: 5,179
6. Mueller LP, Luetzkendorf J, Mueller T, Reichelt K, Simon H, Schmoll HJ: (2006) Presence of mesenchymal stem cells in human bone marrow after exposure to

chemotherapy: evidence of resistance to apoptosis induction. STEM CELLS, 24: 2753-65 [16931776](#)

IF: 7,924

7. Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ: (2006) Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. TUMOR BIOL, 27: 71-83 [16557044](#)
IF: 2,407
8. Schmoll HJ, Apro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY: (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. ANN ONCOL, 17: 1000-1006
IF: 5,179
9. Schmoll HJ, Arnold D: (2006) Update on capecitabine in colorectal cancer. ONCOLOGIST, 11: 1003-1009
IF: 5,206
10. van Cutsem E, Dicato M, Arber N, Benson A, Cunningham D, Diaz-Rubio E, Glimelius B, Goldberg R, Haller D, Haustermans K, Koo-Kang Y, Labianca R, Lang I, Minsky B, Nordlinger B, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Szawlowski A, van de Velde C: (2006) The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. ANN ONCOL, 17: vi 13-18
IF: 5,179
11. Voigt W, Kegel T, Maher G, Jordan K, Mueller L, Schmoll HJ: (2006) Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. ANN ONCOL, 17: 531-533
IF: 5,179

2006 Summe Bewertung = 13,59638

Summe IF = 51,389

Originalarbeiten

1. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van Cutsem E, Köhne CH: (2007) Corrigendum to "Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?". EUR J CANCER, 43: 633
IF: 4,454
2. Jordan K, Grothe W, Schmoll HJ: (2007) Zytostatikaparavasate: Prophylaxe und Therapie. ONKOLOGIE, 6: 55-58
IF: 1,227
3. Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ: (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute

chemotherapy-induced emesis. SUPPORT CARE CANCER, 15: 1023-33 [17205281](#)
IF: 2,122

4. Jordan K, Schmoll HJ, Apro MS: (2007) Comparative activity of antiemetic drugs. CRIT REV ONCOL HEMAT, 61: 162-175
IF: 4,632
5. Jordan K, Sippel C, Schmoll HJ: (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. ONCOLOGIST, 12: 1143-1150
IF: 4,876
6. Lorch JH, Thomas TO, Schmoll HJ: (2007) Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. CANCER RES, 15: 727-734
IF: 7,672
7. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ: (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J CLIN ONCOL, 25: 4217-23 [17548840](#)
IF: 15,484
8. Punt CJ, Buyse M, Koehne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman A, Douillard JY: (2007) Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. JNCI-J NATL CANCER I, 99: 998-1003
IF: 15,678
9. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzen F, Haller DG: (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J CLIN ONCOL, 1: 102-109
IF: 15,484
10. Schmoll HJ, Sargent D: (2007) CAIRO and FOCUS - Author's reply. LANCET, 370: 1905
IF: 28,638
11. Schmoll HJ, Sargent D: (2007) Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? LANCET, 370: 105-107
IF: 28,638
12. Schmoll HJ, Schmiegel W: (2007) VII. Interdisziplinärer Expertenworkshop 2007 "Gastrointestinale Tumore" - Zusammenfassung. ONKOLOGIE, 30: 27
IF: 1,227
13. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PD, Kerr D,

Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J: (2007) The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona 2006. ANN ONCOL, 18: vii1-vii10
IF: 4,875

14. Voigt W, Maher G, Wolf HH, Schmoll HJ: (2007) Human chorionic gonadotropin-induced hyperthyroidism in germ cell cancer--a case presentation and review of the literature. ONKOLOGIE, 30: 330-4 [17585415](#)
IF: 1,227

2007 Summe Bewertung = 47,9707

Summe IF = 136,234

Originalarbeiten

1. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R: (2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: A pooled analysis of randomized trials. J CLIN ONCOL, 20: 5910-5917
IF: 17,157
2. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ: (2008) The combination of oxaliplatin with capecitabine or 5-fluorouracil (5-FU)/ leucovorin in patients with metastatic colorectal cancer (MCRC): a pooled analysis of randomized phase II-III trials. J CLIN ONCOL, 26: 5910-5917
IF: 17,157
3. Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretschmar A, Greil R, Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R, Colorectal Study Group AIO: (2008) Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. CLIN COLORECTAL CANC, 7: 60-4 [18279579](#)
IF: 2,724
4. Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T, Zubel A, Schmoll HJ: (2008) Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ANN ONCOL, 19: 1442-9 [18441330](#)
IF: 4,935
5. Arnold D, Siewczynski R, Kubicka S, Hacker U, Schmoll HJ: (2008) Kolorektales Karzinom - Primärtherapie bei fortgeschrittener Metastasierung. ONKOLOGIE, 31: 3-8
IF: 1,545

6. Cassidy J, Schmoll HJ, Van Cutsem E: (2008) Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J CLIN ONCOL, 26: 2228
IF: 17,157
7. Dietrich A, Mueller T, Paschke R, Kalinowski B, Behlendorf T, Reipsch F, Fruehauf A, Schmoll HJ, Kloft C, Voigt W: (2008) 2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): a novel platinum compound that overcomes cisplatin resistance and induces apoptosis by mechanisms different from that of cisplatin. J MED CHEM, 51: 5413-22 [18698754](#)
IF: 4,898
8. Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, De Santis M, Daugaard G, Flechon A, de Giorgi U, Tjulandin S, Schmoll HJ, Bouzy J, Fossa SD, Fromont G: (2008) Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. ANN ONCOL, 19: 259-264
IF: 4,935
9. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G, O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzen F, Twelves C: (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J CLIN ONCOL, 26: 2118-2123
IF: 17,157
10. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, Gardia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillissen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H: (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. EUR UROL, 53: 497-513
IF: 6,512
11. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, Gardia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillissen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG,

Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H: (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I. EUR UROL, 53: 478-496
IF: 6,512

12. Müller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau H, Hahn SA, Schmoll HJ, Porschen R, Schmiegel W, Graeven U: (2008) Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy . A report of the AIO Colorectal Study Group. INT J COLORECTAL DIS, 23: 1033-39
IF: 1,767

13. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rödel C, Sauer R, Wieder M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C: (2008) [Update S3-guideline "colorectal cancer" 2008]. Z GASTROENTEROL, 46: 799-840 [18759205](#)
IF: 0,88

14. Valentini V, Beets-Tan R, Borrás JM, Krivokapic Z, Leer JW, Pahlman L, Rödel C, Schmoll HJ, Scott N, Velde CV, Verfaillie C: (2008) Evidence and research in rectal cancer. RADIOTHER ONCOL, 87: 449-474
IF: 3,99

15. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J: (2008) The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. ANN ONCOL, 19: vi1-vi8
IF: 4,935

16. Voigt W, Jordan K, Schmoll HJ: (2008) Advances in the prognosis and treatment of medullary or anaplastic thyroid cancer. EUR J ENDOCRINOL, 4: 66-69
IF: 3,791

2008 Summe Bewertung = 16,50952

Summe IF = 116,052

Originalarbeiten

1. Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S, Wiesinger H, Giurescu M, Thiel E, Schmoll HJ: (2009) Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. BRIT J CANCER, 101: 1241-7 [19773753](#)
IF: 4,346
2. Dansranjavin T, Krehl S, Müller T, Müller LP, Schmoll HJ, Dammann RH: (2009) The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. CELL CYCLE, 15: 916-924
IF: 4,087
3. Jahn P, Renz P, Stukenkemper J, Book K, Kuss O, Jordan K, Horn I, Thoke-Colberg A, Schmoll HJ, Landenberger M: (2009) Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. SUPPORT CARE CANCER, 17: 1543-52 [19629539](#)
IF: 2,089
4. Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ: (2009) Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. EUR J CANCER, 45: 1184-7 [19135359](#)
IF: 4,121
5. Jordan K, Behlendorf T, Müller F, Schmoll HJ: (2009) Anthracycline extravasation injuries: management with dexrazoxane. THER CLIN RISK MANAG, 5: 361-6 [19536310](#)
IF: 0
6. Keysser G, Müller L, Schendel M, Schmoll HJ: (2009) [Therapeutic application of mesenchymal stromal cells in autoimmune disease: rationale and initial clinical experience]. Z RHEUMATOL, 68: 220, 222-7 [19384552](#)
IF: 0,401
7. Mueller T, Luetzkendorf J, Nerger K, Schmoll HJ, Mueller LP: (2009) Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells. CELL MOL LIFE SCI, 66: 495-503 [19023518](#)
IF: 6,09
8. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ: (2009) Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. CLIN COLORECTAL CANC, 8: 59-60
IF: 1,764
9. Schmoll HJ, Arnold D: (2009) When Wishful Thinking Leads to a Misty-Eyed Appraisal: The Story of the Adjuvant Colon Cancer Trials With Edrecolomab. J CLIN ONCOL, 27: 1-4
IF: 17,793
10. Schmoll HJ, Jordan K: (2009) Current treatment of high risk testis cancer. EUR J CANCER, 45 Suppl 1: 433-5 [19775661](#)

IF: 4,121

11. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2009) Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ANN ONCOL, 20 Suppl 4: 83-8 [19454474](#)
IF: 5,647
12. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2009) Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ANN ONCOL, 20 Suppl 4: 89-96 [19454475](#)
IF: 5,647
13. Schmoll HJ, Schmiegel W: (2009) Gastrointestinal tumors. Foreward. ONKOLOGIE, 32: 1
IF: 1,234
14. Seliger G, Mueller LP, Kegel T, Kantelhardt EJ, Grothey A, Groe R, Strauss HG, Koelbl H, Thomssen C, Schmoll HJ: (2009) Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. INT J GYNECOL CANCER, 19: 1446-53 [20009905](#)
IF: 2,179
15. Trarbach T, Schmoll HJ: (2009) Rectal cancer and synchronous metastases: resection of primary tumor or not? GASTROEN CLIN BIOL, 33: 1098-1100
IF: 0,928
16. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borrás JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, Quirke P, Schmoll HJ, Sebag-Montefiore D, Taylor I, van Cutsem E, van de Velde C, Cellini N, Latini P, Scientific C: (2009) Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). RADIOTHER ONCOL, 92: 148-163
IF: 4,343
17. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C: (2009) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona 2008. ANN ONCOL, 20: vii1-vii6
IF: 5,647

2009 Summe Bewertung = 21,34746

Summe IF = 70,437

Originalarbeiten

1. Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, Trarbach T, Staib L, Kirchner T, Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P: (2010) Spezielle Therapiesituationen beim metastasierten kolorektalen Karzinom. ONKOLOGIE, 33: 8-18
IF: 1,156
2. Bukur J, Loeffler D, Massa C, Mueller L, Riemann D, Schmoll HJ, Seliger B: (2010) "Tumor immunology meets oncology IV", 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany. CANCER IMMUNOL IMMUN, 59: 955-62 [18751976](#)
IF: 4,293
3. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JR, Bokemeyer C, Schmoll HJ: (2010) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSSG, and Grupo Germinal (EORTC 30974). ANN ONCOL, 22: 1054-1061
IF: 6,452
4. Jordan K, Grothey A, Pelz T, Lautenschläger C, Franke U, Schöber C, Schmoll HJ: (2010) Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. EUR J CANCER CARE, 19: 603-9 [19725867](#)
IF: 1,138
5. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ: (2010) The NK-1 receptor-antagonist aprepitant in high-dose (HD) chemotherapy (HD melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. BONE MARROW TRANSPL, 13: 1-6
IF: 3,66
6. Jordan K, Wolf HH, Voigt W, Kegel T, Mueller LP, Behlendorf T, Sippel C, Arnold D, Schmoll HJ: (2010) Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. BONE MARROW TRANSPL, 45: 1704-9 [20228848](#)
IF: 3,66
7. Lützkendorf J, Müller LP, Müller T, Caysa H, Nerger K, Schmoll HJ: (2010) Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J CELL MOL MED, 14: 2292-304 [19508388](#)
IF: 4,608
8. Matuszczyk A, Petersen S, Voigt W, Kegel T, Dralle H, Schmoll HJ, Bockisch A, Mann K: (2010) Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. HORM METAB RES, 42: 61-4 [19735058](#)
IF: 2,414
9. Mueller T, Mueller LP, Holzhausen HJ, Witthuhn R, Albers P, Schmoll HJ: (2010) Histological evidence for the existence of germ cell tumor cells showing embryonal

carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity.
HISTOCHEM CELL BIOL, 134: 197-204 [20532795](#)
IF: 4,727

10. Peinert S, Grothe W, Stein A, Müller LP, Ruessel J, Voigt W, Schmoll HJ, Arnold D: (2010) Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. THER ADV MED ONCOL, 2: 161-74 [21789132](#)
IF: 0
11. Reinacher-Schick A, Arnold D, Trarbach T, Ridwelski K, Bruch HP, Kirchner T, Kubicka S, Schmoll HJ: (2010) Adjuvante Therapie des Kolonkarzinoms. ONKOLOGIE, 33: 2-7
IF: 1,156
12. Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, Fölsch UR, Frühmorgen P, Graeven U, Heinemann V, Hohenberger W, Holstege A, Junginger T, Kopp I, Kühnbacher T, Porschen R, Propping P, Riemann JF, Rödel C, Sauer R, Sauerbruch T, Schmitt W, Schmoll HJ, Seufferlein T, Zeitz M, Selbmann HK: (2010) S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z GASTROENTEROL, 48: 65-136 [20072998](#)
IF: 1,131
13. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2010) Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 21 Suppl 5: v147-54 [20555066](#)
IF: 6,452
14. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2010) Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 21 Suppl 5: v140-6 [20555065](#)
IF: 6,452
15. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, van de Velde C, Schmoll HJ, Sobrero A, Tabernero J: (2010) Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona 2009. ANN ONCOL, 21: v1-10
IF: 6,452
16. Voigt W, Lorenz K, Schmoll HJ: (2010) Therapie des Schilddrüsenkarzinoms. TUMORDIAGN THER, 1: 18-22
IF: 0
17. Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Hakansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll HJ, Siena S, Tabernero J, van Cutsem E: (2010) Molecularly

targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. CURR OPIN MOL THER, 12: 703-11 [21154162](#)
IF: 4,023

2010 Summe Bewertung = 13,45214

Summe IF = 57,774

Originalarbeiten

1. Abouassaly R, Fossa SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, Sternberg CN: (2011) Sequelae of treatment in long-term survivors of testis cancer. EUR UROL, 60: 516-26 [21684072](#)
IF: 8,493
2. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U: (2011) Gastrointestinale Tumore - interdisziplinäre Diskussion neuer Daten. ONKOLOGIE, 34: 1-31
IF: 0,868
3. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U: (2011) [Gastrointestinal tumors-- interdisciplinary discussion over new data]. ONKOLOGIE, 34 Suppl 3: 1-31 [21577036](#)
IF: 0,868
4. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ: (2011) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSSG, and Grupo Germinal (EORTC 30974). ANN ONCOL, 22: 1054-61 [21059637](#)
IF: 6,425
5. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ: (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J CLIN ONCOL, 29: 1465-71 [21383294](#)
IF: 18,372
6. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ: (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. BONE MARROW TRANSPL, 46: 784-9 [20838387](#)
IF: 3,746
7. Keyszer G, Christopeit M, Fick S, Schendel M, Taute BM, Behre G, Müller LP, Schmoll HJ: (2011) Treatment of severe progressive systemic sclerosis with transplantation of

mesenchymal stromal cells from allogeneic related donors: report of five cases.
ARTHRITIS RHEUM-US, 63: 2540-2 [21547891](#)
IF: 7,866

8. Rüssel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll HJ, Arnold D: (2011) Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab. J CLIN ONCOL, 29: e644-6 [21606410](#)
IF: 18,372
9. Schmoll HJ, Heissner K: (2011) Current treatment of stage I testicular seminoma. ONKOLOGIE, 34: 495-6 [21985846](#)
IF: 0,868
10. Schmoll HJ, Osanto S, Kawai K, Einhorn L, Fizazi K: (2011) Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. UROLOGY, 78: S456-68 [21986225](#)
IF: 2,428
11. Stein A, Hiemer S, Schmoll HJ: (2011) Adjuvant therapy for early colon cancer: current status. DRUGS, 71: 2257-75 [22085384](#)
IF: 4,226
12. Surov A, Fiedler E, Holzhausen HJ, Ruschke K, Schmoll HJ, Spielmann RP: (2011) Metastases to the breast from non-mammary malignancies: primary tumors, prevalence, clinical signs, and radiological features. ACAD RADIOL, 18: 565-74 [21393030](#)
IF: 1,692
13. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E: (2011) Pancreatic cancer treatment and research: an international expert panel discussion. ANN ONCOL, 22: 1500-6 [21199884](#)
IF: 6,425
14. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynn-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalberg J: (2011) The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. ANN ONCOL, 22 Suppl 5: v1-9 [21633049](#)
IF: 6,425

2011 Summe Bewertung = 17,14081

Summe IF = 87,074

Originalarbeiten

1. Calabrò F, Albers P, Bokemeyer C, Martin C, Einhorn LH, Horwich A, Krege S, Schmoll HJ, Sternberg CN, Daugaard G: (2012) The contemporary role of chemotherapy for

advanced testis cancer: a systematic review of the literature. EUR UROL, 61: 1212-21 [22464311](#)

IF: 10,476

2. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM: (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. LANCET ONCOL, 13: 1225-33 [23168362](#)
IF: 25,117
3. Nagtegaal ID, Quirke P, Schmoll HJ: (2012) Has the new TNM classification for colorectal cancer improved care? NAT REV CLIN ONCOL, 9: 119-23 [22009076](#)
IF: 15,031
4. Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, Piccart-Gebhart MJ, de Azambuja E: (2012) Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. ANN ONCOL, 23: 853-9 [21821551](#)
IF: 7,384
5. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E: (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J CLIN ONCOL, 30: 3588-95 [22965961](#)
IF: 18,038
6. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A: (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. ANN ONCOL, 23: 2479-516 [23012255](#)
IF: 7,384
7. Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ: (2012) Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC CANCER, 12: 356 [22897915](#)
IF: 3,333

- Stein A, Hiemer S, Jordan K, Arnold D, Schmoll HJ: (2012) Administration of chemotherapy by an arteriovenous fistula in a patient with metastatic rectal cancer after life-threatening, port thrombosis-associated cava superior syndrome. An option for patients without possibility of peripheral or central venous access. ONKOLOGIE, 35: 440-2 [22846976](#)
IF: 1

2012 Summe Bewertung = 16,03414

Summe IF = 87,763

Originalarbeiten

- Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT: (2013) Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. CANCER TREAT REV, 39: 113-7 [23062719](#)
IF: 6,466
- Bernig T, Jahn F, Witkowsky S, Huehn R, Hentschel A, Kegel T, Schmoll HJ, Körholz D: (2013) Treatment of adolescents and young adults (AYA) with cancer in a multidisciplinary setting: on the way to a highly specialized AYA unit. KLIN PADIATR, 225: 335-8 [24166088](#)
IF: 0
- Christopeit M, Janssen N, Weber T, Bacher U, Lautenschläger C, Oehme A, Kekulé AS, Schmoll HJ: (2013) Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia. LEUKEMIA LYMPHOMA, 54: 133-7 [22721496](#)
IF: 2,605
- Christopeit M, Lindner A, Surov A, Weber T, Vehreschild MJGT, Bialek R, Schmoll HJ: (2013) Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia. MYCOSES, 56: 90-2 [22889321](#)
IF: 1,805
- Dralle H, Musholt TJ, Schabram J, Steinmüller T, Frilling A, Simon D, Goretzki PE, Niederle B, Scheuba C, Clerici T, Hermann M, Kußmann J, Lorenz K, Nies C, Schabram P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll HJ, Mühlenberg R, Schober O, Rimmele H, Machens A, German Societies of General and Visceral Surgery Endocrinology Nuclear Medicine Pathology Radiooncology Oncological Hematology and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V: (2013) German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. LANGENBECK ARCH SURG, 398: 347-75 [23456424](#)
IF: 2,16
- Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM: (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. BRIT J CANCER, 108: 1316-23 [23449351](#)

IF: 4,817

7. Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V, ESMO Guidelines Working Group: (2013) Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 24 Suppl 6: vi125-32 [24078656](#)
IF: 6,578
8. Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W, Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e. V, Deutschen Krebshilfe e. V: (2013) [S3-guideline colorectal cancer version 1.0]. Z GASTROENTEROL, 51: 753-854 [23955142](#)
IF: 1,671
9. Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U: (2013) Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ANN ONCOL, 24: 1580-7 [23463625](#)
IF: 6,578
10. Stein A, Schmoll HJ: (2013) Systemic treatment of liver metastases from colorectal cancer. THER ADV MED ONCOL, 5: 193-203 [23634197](#)
IF: 0
11. Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, Haq A, Schmoll HJ, Tabernero J: (2013) Improving outcomes in colorectal cancer: where do we go from here? EUR J CANCER, 49: 2476-85 [23642327](#)
IF: 4,819
12. van de Velde CJH, Aristei C, Boelens PG, Beets-Tan RGH, Blomqvist L, Borràs JM, van den Broek CBM, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CAM, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Pålman L, Quirke P, Rödel C, Roth A, Rutten HJT, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V, European Registration of Cancer Care: (2013) EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. EUR J CANCER, 49: 2784-90 [23769991](#)
IF: 4,819

2013 Summe Bewertung = 3,29282

Summe IF = 42,318

Originalarbeiten

1. Bach AG, Schmoll HJ, Beckel C, Behrmann C, Spielmann RP, Wienke A, Abbas J, Surov A: (2014) Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events. ACTA RADIOL, 55: 45-53 [23864061](#)
IF: 1,603
2. Breugom AJ, Boelens PG, van den Broek CBM, Cervantes A, Van Cutsem E, Schmoll HJ, Valentini V, van de Velde CJH: (2014) Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. ANN ONCOL, 25: 1485-92 [24671742](#)
IF: 7,04
3. Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, Saif MW, McKenna E, Lee S, Schmoll HJ: (2014) Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. BRIT J CANCER, 110: 1438-45 [24548866](#)
IF: 4,836
4. Kreissl MC, Jacob C, Führer D, Karges W, Luster M, Lux MP, Mann K, Mittendorf T, Schott M, Spitzweg C, Schmoll HJ: (2014) Best supportive care from the conservative/non-surgical perspective and its costs in the treatment of patients with advanced medullary thyroid cancer: results of a Delphi panel. ONCOL RES TREAT, 37: 316-22 [24903762](#)
IF: 0
5. Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, Scalone S, Tartuferi L, Buonadonna A, Ejiófor L, Schmoll HJ: (2014) Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. ANN ONCOL, 25: 1059-64 [24558023](#)
IF: 7,04
6. Riemann JF, Schröder C, Kallenbach M, Giersiepen K, Schmoll HJ: (2014) Benefits and risks of colorectal cancer screening. ONCOL RES TREAT, 37 Suppl 3: 11-20 [25195828](#)
IF: 0
7. Schmoll HJ, Stein A: (2014) Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. NAT REV CLIN ONCOL, 11: 79-80 [24445520](#)
IF: 14,18
8. Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D: (2014) Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. LANCET ONCOL, 15: 1481-92 [25456367](#)
IF: 24,69
9. Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, Mayer F, Andel J, Ziebermayr R, Scheithauer W: (2014) Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J CANCER RES CLIN, 140: 1615-24 [24816725](#)

IF: 3,081

10. Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ: (2014) Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. ACTA ONCOL, 53: 392-8 [24024696](#)
IF: 2,997
11. van de Velde CJH, Boelens PG, Borrás JM, Coebergh JW, Cervantes A, Blomqvist L, Beets-Tan RGH, van den Broek CBM, Brown G, Van Cutsem E, Espin E, Haustermans K, Glimelius B, Iversen LH, van Krieken JH, Marijnen CAM, Henning G, Gore-Booth J, Meldolesi E, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Páhlman L, Quirke P, Rödel C, Roth A, Rutten H, Schmoll HJ, Smith JJ, Tanis PJ, Taylor C, Wibe A, Wiggers T, Gambacorta MA, Aristei C, Valentini V: (2014) EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. EUR J CANCER, 50: 1.e1-1.e34 [24183379](#)
IF: 5,417

2014 Summe Bewertung = 21,83797

Summe IF = 70,884

Originalarbeiten

1. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D: (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. ONCOLOGIST, 20: 450-8 [25795636](#)
IF: 4,789
2. Bauer A, Vordermark D, Seufferlein T, Schmoll HJ, Dralle H, Mau W, Unverzagt S, Boese S, Fach EM, Landenberger M: (2015) Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC CANCER, 15: 997 [26694748](#)
IF: 3,265
3. Grünwald V, Keilholz U, Boehm A, Guntinas-Lichius O, Hennemann B, Schmoll HJ, Ivanyi P, Abbas M, Lehmann U, Koch A, Karch A, Zörner A, Gauler TC: (2015) TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). ANN ONCOL, 26: 561-7 [25527417](#)
IF: 9,269
4. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM, Gibson F: (2015) A review of the evolution of systemic chemotherapy in the management of colorectal cancer. CLIN COLORECTAL CANC, 14: 1-10 [25579803](#)
IF: 3,09
5. Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ: (2015) Impact of age and medical comorbidity on

adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. ANN ONCOL, 26: 715-24 [25595934](#)
IF: 9,269

6. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D: (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. LANCET ONCOL, 16: 1355-69 [26361971](#)
IF: 26,509
7. Jahn F, Jordan K, Behlendorf T, Globig C, Schmoll HJ, Müller-Tidow C, Jordan B: (2015) Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis. ONCOLOGY-BASEL, 89: 137-42 [25791073](#)
IF: 2,152
8. Renfro LA, Grothey A, Kerr D, Haller DG, André T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group, Adjuvant Colon Cancer Endpoints ACCENT Group: (2015) Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†. ANN ONCOL, 26: 950-8 [25697217](#)
IF: 9,269
9. Ruff P, Ferry DR, Lakomý R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E: (2015) Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. EUR J CANCER, 51: 18-26 [25466509](#)
IF: 6,163
10. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG: (2015) Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J CLIN ONCOL, 33: 3733-40 [26324362](#)
IF: 20,982
11. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ: (2015) A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. JNCI-J NATL CANCER I, 107: djv258 [26405092](#)
IF: 11,37

12. Shi Q, de Gramont A, Grothey A, Zalcborg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJA, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ: (2015) Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J CLIN ONCOL, 33: 22-8 [25385741](#)
IF: 20,982
13. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ: (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. CRIT REV ONCOL HEMAT, 94: 31-44 [25577571](#)
IF: 5,039

2015 Summe Bewertung = 14,31826

Summe IF = 132,148

Originalarbeiten

1. Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørlov JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG): (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. LANCET HAEMATOL, 3: e217-27 [27132696](#)
IF: 7,123
2. Gormly KL, Coscia C, Wells T, Tebbutt N, Harvey JA, Wilson K, Schmoll HJ, Price T: (2016) MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial. J MED IMAG RADIAT ON, 60: 607-615 [27397855](#)
IF: 1,189
3. Lutz MP, Zalcborg JR, Glynn-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F: (2016) Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]. EUR J CANCER, 68: 208-209 [27717654](#)
IF: 6,029
4. Lutz MP, Zalcborg JR, Glynn-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A,

Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Puciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F: (2016) Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. EUR J CANCER, 63: 11-24 [27254838](#)

IF: 6,029

5. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A: (2016) Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. ANN ONCOL, 27: 1746-53 [27358379](#)
IF: 11,855
6. Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR: (2016) Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC CANCER, 16: 699 [27582078](#)
IF: 3,288
7. Papamichael D, Renfro LA, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E, Schmoll HJ, Labianca R, André T, O'Connell M, Alberts SR, Haller DG, Kountourakis P, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group: (2016) Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. J GERIATR ONCOL, 7: 422-429 [27468630](#)
IF: 2,852
8. Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SE, Arnold D: (2016) Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. ANN ONCOL, 27: 2203-2210 [27753609](#)
IF: 11,855
9. Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ: (2016) Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J CLIN ONCOL, 34: 144-50 [26503203](#)
IF: 24,008

10. Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ: (2016) Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J CLIN ONCOL, 34: 843-53 [26811529](#)
IF: 24,008
11. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJG, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D: (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. ANN ONCOL, 27: 1386-422 [27380959](#)
IF: 11,855
12. Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guenec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J: (2016) Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. TARGET ONCOL, 11: 383-400 [26706237](#)
IF: 3,438
13. Widder M, Lützkendorf J, Caysa H, Unverzagt S, Wickenhauser C, Benndorf RA, Schmoll HJ, Müller-Tidow C, Müller T, Müller LP: (2016) Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β 1-integrin-dependent mechanism. INT J CANCER, 138: 964-75 [26356035](#)
IF: 6,513

2016 Summe Bewertung = 2,61932

Summe IF = 120,042

Originalarbeiten

1. Bleiberg H, Decoster G, de Gramont A, Rougier P, Sobrero A, Benson A, Chibaudel B, Douillard JY, Eng C, Fuchs C, Fujii M, Labianca R, Larsen AK, Mitchell E, Schmoll HJ, Sprumont D, Zalberg J: (2017) A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. ANN ONCOL, 28: 922-930 [28453700](#)
IF: 11,855
2. Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ,

Tournigand C, de Gramont A: (2017) How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. ANN ONCOL, 28: 2077-2085 [28430862](#)
IF: 11,855

3. Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J, PETACC8 Study Investigators, Austrian Breast and Colorectal cancer Study Group (ABCSCG), Belgian Group of Digestive Oncology (BGDO), Lone Nørgård Petersen, Fédération Francophone de Cancérologie Digestive (FFCD), Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER), Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO), Arbeitsgemeinschaft Internistische Onkologie (AIO), Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), Gruppo Oncologico dell'Italia Meridionale (GOIM), Istituto Oncologico Romagnolo (IOR), Gruppo Cooperativo Chirurgico Italiano (GOCCI), Gruppo Oncologico Nord Ovest (GONO), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD APIO), Grupo Español para el Tratamiento de los Tumores Digestivos (TTD), John Allen Bridgewater: (2017) Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. EUR J CANCER, 82: 16-24 [28651158](#)
IF: 6,029
4. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG): (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. LANCET HAEMATOL, 4: e510-e523 [29054815](#)
IF: 7,123
5. Lützkendorf J, Wieduwild E, Nerger K, Lambrecht N, Schmoll HJ, Müller-Tidow C, Müller LP: (2017) Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. PLoS One, 12: e0169921 [28081228](#)
IF: 2,806
6. Nagtegaal ID, Schmoll HJ: (2017) Colorectal cancer: What is the role of lymph node metastases in the progression of colorectal cancer? NAT REV GASTRO HEPAT, 14: 633-634 [28930293](#)
IF: 13,678

7. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ, ARCAD Clinical Trials Program: (2017) Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. J CLIN ONCOL, 35: 1929-1937 [28414610](#)
IF: 24,008
8. Schaffrath J, Schmoll HJ, Voigt W, Müller LP, Müller-Tidow C, Mueller T: (2017) Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS One, 12: e0178930 [28591197](#)
IF: 2,806
9. Schmidt H, Boese S, Bauer A, Landenberger M, Lau A, Stoll O, Schmoll HJ, Mauz-Koerholz C, Kuss O, Jahn P: (2017) Interdisciplinary care programme to improve self-management for cancer patients undergoing stem cell transplantation: a prospective non-randomised intervention study. EUR J CANCER CARE, 26: x [26857103](#)
IF: 2,104
10. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ: (2017) Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. INT J CANCER, 140: 431-439 [27681944](#)
IF: 6,513
11. Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcborg JR, Fondation Aide et Recherche en Cancerologie Digestive Group: (2017) Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI-J NATL CANCER I, x: x [29267900](#)
IF: 12,589

2017 Summe Bewertung = 8,48761

Summe IF = 101,366

Originalarbeiten

1. Schmoll HJ, Arnold D, de Gramont A, Ducreux M, Grothey A, O'Dwyer PJ, Van Cutsem E, Hermann F, Bosanac I, Bendahmane B, Mancao C, Tabernero J: (2018) MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J CANCER RES CLIN, x: x [29644408](#)

IF: 3,503

2018 Summe Bewertung = 1,16767

Summe IF = 3,503

Comments and Letter

1. Schmoll HJ: (2010) S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug? LANCET ONCOL, 11: 808-809
IF: 17,764

2010 Summe Bewertung = 1,7764

Summe IF = 17,764

Comments and Letter

1. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C, AWMF, AWMF: (2011) [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z GASTROENTEROL, 49: 461-531 [21476183](#)
IF: 0,896
2. Schmoll HJ: (2011) Do we need oncology trials tailored for the elderly or frail? LANCET, 377: 1725-7 [21601694](#)
IF: 38,278
3. Schmoll HJ, Hallek M: (2011) Perspectives for onkologie. ONKOLOGIE, 34: 659 [22156443](#)
IF: 0,868

2011 Summe Bewertung = 3,87148

Summe IF = 40,042

Comments and Letter

1. Wass M, Behlendorf T, Schädlich B, Mottok A, Rosenwald A, Schmoll HJ, Jordan K: (2014) Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. EUR J HAEMATOL, 92: 268-70 [24330038](#)
IF: 2,066

2014 Summe Bewertung = 0,01377

Summe IF = 2,066

Comments and Letter

1. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, ESMO/ASCO Global Curriculum Working Group: (2016) ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. ANN ONCOL, 27: 1378-81
IF: 11,855
2. Schmoll HJ: (2016) Targeting HER2: precision oncology for colorectal cancer. LANCET ONCOL, 17: 685-686 [27108244](#)
IF: 33,9

2016 Summe Bewertung = 3,78517

Summe IF = 45,755

Comments and Letter

1. Schmoll HJ: (2017) Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours? LANCET ONCOL, 18: 1138-1139 [28781172](#)
IF: 33,9

2017 Summe Bewertung = 3,39

Summe IF = 33,9